Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense
Despite scant evidence that it works, the drug, Aduhelm, is predicted to generate billions of dollars in revenue, much of it from Medicare.
- Next story Using light to monitor cancer
- Previous story New heart metric may improve survival for heart-failure patients, study finds
Explore more
- COVID-19 public health messages have been all over the place—but researchers can do better
Persuading people to get a COVID-19 vaccine remains a challenge even as... - Apple’s App Store Fees Are Too High
Apple doesn’t deserve 30 percent of all the money people spend in... - What you need to listen to lossless audio and Dolby Atmos on Apple Music
With Apple Music poised to open the gates to Dolby Atmos for... - How a Traveling Tennis Racket Stringer Spends His Sundays
Pierre Reveilles, who carries a 70-pound machine on his bike, can often... - France kept classrooms open ‘at all costs.’ Some say the price was too high
Grace was full of hope as she entered the final stretch of... - Myanmar Protests, and Killings, Continue
The death toll has passed 700, with more than 80 killed on... - Suppressing the impact of COVID-19 using controlled testing and isolation
The outbreak of COVID-19 has revealed the widespread effects a pandemic can... - Astropsychology: How to stay sane on Mars
The first humans who visit Mars will face countless challenges, but perhaps... - See Jill Biden and the Duchess of Cambridge host school roundtable
First Lady Jill Biden and Catherine, Duchess of Cambridge, are participating in... - Nicki Minaj is obsessed with ‘The Crown’ — like, really obsessed
Nicki Minaj says she is “obsessing” over “The Crown” after binge-watching seasons...